JP Morgan Healthcare Conference Giovanni Caforio Chief Executive Officer January 12, 2016 1
Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated as a result of various important factors, including those discussed in the company s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. This presentation also contains certain non-gaap financial measures, adjusted to include certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-gaap financial measures to the most comparable GAAP measures are available on the company s website at www.bms.com. 2 2
Our Strategic Foundation Best of BIOTECH Best of PHARMA Diversified Specialty BioPharma INNOVATE INTEGRATE IMPROVE People helping patients in their fight against serious disease 3
2015: Beginning A New Chapter Leading in Immuno-Oncology Diversified in-line portfolio 3 7 Early Trial Stops FDA Approvals 43 Global launches A Strong Foundation for Future Growth 4
Strategic Priorities Drive business performance Leadership in Immuno-Oncology Diversify for long-term growth Business Development and Capital Allocation 5
2015: Leading in Immuno-Oncology LUNG MELANOMA RENAL Only PD-1 indicated for all 2 nd line NSCLC patients No testing requirement Strong access and reimbursement Broad range of treatment options (Mono and combination therapy, 1 st and 2 nd line, adjuvant) First I-O combination regimen approved First I-O agent in 2 nd line Meaningful improvement over a standard of care 6
2015: Leading in Immuno-Oncology Strong US commercial execution I-O Weekly Sales Trends BMS I-O Portfolio Opdivo Yervoy Keytruda 1/2 1/9 1/16 1/23 1/30 2/6 2/13 2/20 2/27 3/6 3/13 3/20 3/27 4/3 4/10 4/17 4/24 5/1 5/8 5/15 5/22 5/29 6/5 6/12 6/19 6/26 7/3 7/10 7/17 7/24 7/31 8/7 8/14 8/21 8/28 9/4 9/11 9/18 9/25 10/2 10/9 10/16 10/23 10/30 11/6 11/13 11/20 11/27 12/4 12/11 Note: This information is an estimate derived from the use of information under license from the following IMS Health information services: Xponent & DDD weekly dollars, for the period of 1/2/2015 through 12/31/2015. IMS expressly reserves all rights, including rights of copying, distribution and republication. Total IO Market Weekly IMS DDD + Xponent 7
2016: Leading in Immuno-Oncology Potentially Registrational Data Tumor Hodgkin Lymphoma CheckMate -205 Head and Neck CheckMate -141 Non-Hodgkin Lymphoma CheckMate -139 Bladder CheckMate -275 Glioblastoma CheckMate -143 1L NSCLC CheckMate -026 Study Design Monotherapy single arm study in second line Monotherapy vs. standard of care in second line Monotherapy single-arm study in relapsed/refractory diffuse large B-cell lymphoma Monotherapy single arm study in second line bladder Monotherapy vs. standard of care in recurrent glioblastoma Monotherapy vs. chemo in first-line PD-L1 expressers 8
2016: Diversifying in Immuno-Oncology Next wave of innovation: addressing unmet need Improve outcomes through combinations Patients who do not respond to Opdivo +/- Yervoy Patients who progress after treatment with Opdivo +/- Yervoy Additional tumors, including where signals are not sufficient 9
2016: Diversifying in Immuno-Oncology Next wave of innovation: areas of focus Priming & Activation T Cell Trafficking and Infiltration T Cell Activation Antigen Presentation Antigen Release 8 Additional I-O Assets in Clinical Development T cell anti-lag3 Urelumab (anti-cd137) anti-gitr anti-ox40 Tumor Microenvironment anti-csf1r anti-cd73 IDO NK cell NK Cell Activation Lirilumab (anti-kir) BMS assets beginning clinical studies in 2016 10
Strong performance trends establishing global leadership 80% U.S. NBRx NOAC Market Share Cardiologists (AFib + VTE-Tx) 80% U.S. NBRx NOAC Market Share All Physicians (AFib + VTE-Tx) 70% 70% AF/VTE-Tx Share 60% 50% 40% 30% AF/VTE-Tx Share 60% 50% 40% 30% 20% 20% 10% 10% 0% 10/24/14 11/21/14 12/19/14 1/16/15 2/13/15 3/13/15 4/10/15 5/8/15 6/5/15 7/3/15 7/31/15 8/28/15 9/25/15 0% 10/24/14 11/21/14 12/19/14 1/16/15 2/13/15 3/13/15 4/10/15 5/8/15 6/5/15 7/3/15 7/31/15 8/28/15 9/25/15 Eliquis AF/VTE-Tx Pradaxa Total Xarelto AF/VTE-TX Savaysa Total Note: Eliquis and Xarelto (all form strengths) are factored for AF and VTE-Tx indications. Pradaxa and Savaysa are unfactored and include volume across all approved indications. Source: IMS SDI VECTOR. NBRx (New to Brand Rx) = Naïve + Switch to Rx. 11
Pursuing Transformational Medicines Beyond Immuno-Oncology Cardiovascular Heart Failure Thrombosis Immunoscience Novel mechanisms in RA and IBD Lupus Genetically Defined Diseases Monogenic diseases Sentinel populations (eg, Duchenne Muscular Dystrophy, Progressive Supranuclear Palsy) Fibrotic Diseases Lung Liver Kidney 12
Capital Allocation: A Balanced Approach Continue to be in a solid financial position: Strong balance sheet Business development remains a top priority Dividend commitment 7 th consecutive annual increase 13
Select Recent Partnerships I-O Fibrotic Diseases Immunoscience Cardiovascular Academic Partnerships 14
BMS: Poised for Growth Significant growth opportunity driven by I-O and Eliquis Strategic investments behind growth brands Advancing a diverse and innovative pipeline Balanced approach to capital allocation Focused business development 15
JP Morgan Healthcare Conference Giovanni Caforio Chief Executive Officer January 12, 2016 16